<DOC>
	<DOC>NCT00660907</DOC>
	<brief_summary>This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.</brief_summary>
	<brief_title>Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Type 2 Diabetes Treated with oral antidiabetic drug therapy therapy including Metformin for at least 8 weeks prior to enrolment HbA1c &gt;6.5% and &lt;/=10% Type 1 Diabetes Insulin therapy within one year of enrolment Renal (kidney) failure or dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Dapagliflozin</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>metformin</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>